SEC Form 3 · accession 0001144204-15-002480
Amarantus Bioscience Holdings, Inc. · AMBS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Wesley Commissiong
Officer — Chief Scientific Officer · Director
Period of report
Aug 2, 2013
Accepted (ET)
Jan 15, 2015 · 9:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001424812
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 19,994,190 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common Stock | $0.0237 | holding | — | — | — | Apr 10, 2011 | Apr 10, 2021 | Common Stock | 131,557 | — | D |
| Series C Convertible Preferred StockF2,F1 | — | holding | — | — | — | Apr 3, 2013 | — | Common Stock | 200,000 | — | D |
| Warrants to Purchase Common Stock | $0.06 | holding | — | — | — | Oct 2, 2014 | Oct 2, 2016 | Common Stock | 138,889 | — | D |
| Options to Purchase Common StockF3 | $0.08 | holding | — | — | — | Jan 12, 2015 | Jan 12, 2025 | Common Stock | 3,500,000 | — | D |
Explanation of responses
- F1Not applicable.
- F2Each share of Series C Convertible Preferred Stock is convertible into 1 shares of the Issuer's common stock.
- F3Granted to Reporting Person by the Issuer pursuant to the Reporting Person's employment agreement with the Issuer, and shall vest in equal monthly installments beginning on the date of grant for a period of 36 months until it is entirely vested, subject to continued employment with the Issuer